$Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis$

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis

Background Checkpoint inhibitor pneumonitis (CIP) that does not respond to corticosteroids is termed steroid-refractory CIP. We aimed to find risk factors of steroid-refractory CIP and evaluate the management strategies of immunomodulators (IMs).Methods Patients with CIP were identified between Augu...

Full description

Bibliographic Details
Main Authors:	Hong Sun, Yuan Shen, Hui Guo, Yanlin Li, Xiaohui Jia, Yajuan Zhang, Yonghao Du, Yuzhu Chang, Ziyang Mao, Mengjie Liu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/11/6/e006982.full

Similar Items

Correction: Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
Published: (2023-12-01)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
by: Yanlin Li, et al.
Published: (2022-08-01)

Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
by: Kuan-Chang Lai, et al.
Published: (2022-08-01)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
by: Lei Pan, et al.
Published: (2023-01-01)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
by: Hui Xing, et al.
Published: (2023-02-01)

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
by: Dirk Tomsitz, et al.
Published: (2023-04-01)

Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Kathryn A. Lai, et al.
Published: (2020-11-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
by: Lei Zheng, et al.
Published: (2021-01-01)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Published: (2023-11-01)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Published: (2022-09-01)

Cavitation-mediated immunomodulation and its use with checkpoint inhibitors
by: Maardalen, M, et al.
Published: (2023)

Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors
by: Matilde Maardalen, et al.
Published: (2023-08-01)

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
by: Shasha Guan, et al.
Published: (2023-01-01)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
by: Michael B Atkins, et al.
Published: (2020-05-01)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
by: Douglas B Johnson, et al.
Published: (2023-12-01)

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
by: Mei-Xi Lin, et al.
Published: (2024-02-01)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Pierpaolo Correale, et al.
Published: (2020-08-01)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
by: Li Gong, et al.
Published: (2023-06-01)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
by: Wenxian Wang, et al.
Published: (2022-12-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
by: Xiaotong Lu, et al.
Published: (2022-06-01)

Topical non-steroidal immunomodulators in dermatology
by: Priya P Kadu
Published: (2023-01-01)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
by: Leslie E. Kao, et al.
Published: (2023-10-01)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
by: Jie Huang, et al.
Published: (2023-01-01)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
by: Yasuki Uchida, et al.
Published: (2022-05-01)

The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study
by: Hui Huang, et al.
Published: (2024-01-01)

Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images
by: Peixin Tan, et al.
Published: (2022-07-01)

Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the Dose–Volume–Effect Correlation
by: Kim Melanie Kraus, et al.
Published: (2022-06-01)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
by: Qian Zhang, et al.
Published: (2023-02-01)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)

Steroid Refractory Immune Checkpoint Induced Acute Interstitial Nephritis Salvaged by Mycophenolate Mofetil
by: Prashanth Moku, et al.
Published: (2023-04-01)

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
by: Li Pang, et al.
Published: (2023-03-01)

1265 Single-institution retrospective review of patient’s diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
by: Antonious Hazim, et al.
Published: (2023-11-01)

Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer
by: WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi
Published: (2022-06-01)

1298 Radiomics features to predict immune checkpoint inhibitor-related pneumonitis (CIP) in NSCLC patients treated with immunotherapy
by: Young Kwang Chae, et al.
Published: (2023-11-01)

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
by: Xiaoyu Liu, et al.
Published: (2023-04-01)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
by: Yang Shu, et al.
Published: (2023-09-01)

Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response
by: Stefanovic F, et al.
Published: (2022-08-01)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
by: Antonio Riva, et al.
Published: (2023-03-01)